2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-161793
    (S,R,S)-AHPC-NHCO-C-O-C5-N3 2816967-28-7 98%
    (S,R,S)-AHPC-NHCO-C-O-C5-N3 is a conjugate of ligand for E3 ligase (HY-125845) and linker (HY-161792). (S,R,S)-AHPC-NHCO-C-O-C5-N3 can be utilized for synthesis of PROTAC SARS-CoV-2 Mpro degrader-3 (HY-161789).
    (S,R,S)-AHPC-NHCO-C-O-C5-N3
  • HY-161804
    GNF-2-deg 98%
    GNF-2-deg is a PROTAC degrader for dengue virus envelope protein (DENV E protein) with DC50 of 0.83 μM. GNF-2-deg prevents viral entry by inhibiting E-mediated membrane fusion, prevents virion production by protein degradation, and thereby exhibits antiviral activity against DENV 2 with EC90 of 3.5 μM. GNF-2-deg exhibits antiviral activity against ZIKV, JEV, WNV and YFV with EC90 of 1.96-7.79 μM. (Pink: ligand for target protein (HY-161805); Black: linker (HY-42149); Blue: ligand for E3 ligase (HY-23095))
    GNF-2-deg
  • HY-161823
    Anti-MRSA agent 13 98%
    Anti-MRSA agent 13 (Compound 9b) is an agent against methicillin-resistant Staphylococcus aureus (MRSA), exhibiting a minimum inhibitory concentration (MIC) of 0.5–2 μg/mL against clinically isolated MRSA strains. Anti-MRSA agent 13 possesses favorable biosafety, plasma tolerance stability, and a low tendency to develop resistance. Anti-MRSA agent 13 disrupts cell walls and membranes, reduces metabolic activity, causes oxidative damage, affects DNA function, and ultimately leads to MRSA death through multi-target synergies.
    Anti-MRSA agent 13
  • HY-161844
    Virapinib 1794091-10-3 98%
    Virapinib is a macropinocytosis inhibitor with antiviral activity. Virapinib exhibits broad-spectrum antiviral activity against SARS-CoV-2, monkeypox virus, tick-borne encephalitis virus, and Ebola pseudotyped vesicular stomatitis virus, and it enhances Dengue Virus infection. Virapinib blocks viral entry by inhibiting macropinocytosis, reduces syncytium formation in SARS-CoV-2-infected cells, and impairs cellular entry of SARS-CoV-2 variants. Virapinib upregulates the expression of genes related to sterol biosynthesis. Virapinib can be used in studies related to COVID-19, monkeypox, tick-borne encephalitis, and Ebola virus infection.
    Virapinib
  • HY-161870
    Antibiotic adjuvant 1 2351883-15-1 98%
    Antibiotic adjuvant 1 (compound 3e) is an antibiotic adjuvant that presents insufficient antibacterial activity (MIC > 128 µg/mL) and potentiate the activity of Cloxacillin (HY-B0466A)(66-fold) with synergistic effect.
    Antibiotic adjuvant 1
  • HY-161877
    GS-7682 2694736-39-3 98%
    GS-7682 is an antiviral compound. GS-7682 has inhibitory activity against pneumoviruses and picornaviruses. GS-7682 can be used in the study of respiratory diseases such as asthma and chronic obstructive pulmonary disease.
    GS-7682
  • HY-161890
    Antimycobacterial agent-8 98%
    Antimycobacterial agent-8 (Compound 49) is an inhibitor for DNA gyrase. Antimycobacterial agent-8 exhibits antibacterial activity against Mycobacterium tuberculosis and M. abscessus with MIC90 of 2.5 μM and 0.63 μM. Antimycobacterial agent-8 exhibits good plasma protein binding ability in mice.
    Antimycobacterial agent-8
  • HY-161893
    Anti-MRSA agent 15 98%
    Anti-MRSA agent 15 (Compound 9o10) exhibits antibacterial activity, that inhibits methicillin-resistant Staphylococcus aureus (MRSA) with a MIC of 0.0625 μg/mL. Anti-MRSA agent 15 exhibits low hemolysis and low cytotoxicity. Anti-MRSA agent 15 exhibits anti-infective in mice.
    Anti-MRSA agent 15
  • HY-161902
    MI-1904 3033379-90-4 98%
    MI-1904 is the inhibitor for matriptase/TMPRSS2, that exhibits antiviral activity against influenza virus H1N1 and H9N2. MI-1904 blocks the cleavage of glycoproteins on the viral surface, prevents the virus from binding to host cell receptors, and thus inhibits the entry and replication of the virus.
    MI-1904
  • HY-161919
    SARS-CoV-2 3CLpro-IN-25 98%
    SARS-CoV-2 3CLpro-IN-25 (compound 56) inhibits the SARS-CoV-2 3CLpro with the IC50 of 70 nM and displays antiviral activity in cells with the EC50 of 3.1 μM.
    SARS-CoV-2 3CLpro-IN-25
  • HY-161921
    Antifungal agent 108 98%
    Antifungal agent 108 (compound 14d), an original imidazo[1,2-b]pyridazine derivative, shows potent antifungal activity against Madurella mycetomatis (MM55 strain) with an IC50 of 0.9 μM. Antifungal agent 108 exhibits an IC50 of 14.3 μM on cell viability of NIH-3T3 murine fibroblast.
    Antifungal agent 108
  • HY-161922
    Antibacterial agent 235 98%
    Antibacterial agent 235 (compound thy2I) shows antibacterial activity with minimum inhibitory concentration (MIC) values ranging from 0.5 μg/mL to 8 μg/mL. Antibacterial agent 235 could kill both gram-positive and gram-negative bacteria via a membrane-targeting mechanism of action with a low frequency of resistance.
    Antibacterial agent 235
  • HY-161924
    HIV-1 inhibitor-73 98%
    HIV-1 inhibitor-73 (compound 13c) is a potent anti-HIV-1 agent, against the whole tested viral panel with EC50 ranging from 4.68 to 229 nM.
    HIV-1 inhibitor-73
  • HY-161945
    IN-RNA-IN-2 98%
    IN-RNA-IN-2 (compound 1a) is an inhibitor (IC50=70 nM) of the interaction between HIV-1 integrase and the viral RNA genome. IN-RNA-IN-2 exerts its anti-HIV activity by inhibiting the viral replication process.
    IN-RNA-IN-2
  • HY-161980
    Topoisomerases/ribosomes-IN-1 98%
    Topoisomerases/ribosomes-IN-1 (compound 30f) is an inhibitor of ribosomes and topoisomerases, and has inhibitory effects on constitutively macrolide-resistant bacteria. Topoisomerases/ribosomes-IN-1 can inhibit bacterial protein synthesis (IC50: 0.647 μM) and DNA replication (IC50: 0.218 μM).
    Topoisomerases/ribosomes-IN-1
  • HY-161983
    Neuraminidase-IN-22 98%
    Neuraminidase-IN-22 (compound 3e) is a potent, selective and orally active neuraminidase inhibitor with an IC50 value of 0.03 µM. Neuraminidase shows cytotoxicity and anti-influenza A virus activity.
    Neuraminidase-IN-22
  • HY-161984
    HDAC-IN-76 98%
    HDAC-IN-76 (compound 6i) is a histone deacetylase (HDAC) inhibitor. HDAC-IN-76 IC50 values of 30 nM and 98 nM for Pf3D7 (chloroquine (HY-17589A) drug-susceptible strain) and PfDd2 (chloroquine (HY-17589A) drug-resistant strain), has a highly potent antimalarial activity against asexual blood-stage Plasmodium, respectively, and exhibits selective inhibition against parasites, with IC50 values of 7 nM and 9 nM for human HDAC1 and HDAC6, respectively, while inhibiting PfHDAC1.
    HDAC-IN-76
  • HY-161986
    HIV-1 inhibitor-74 98%
    HIV-1 inhibitor-74 (compound 10c) is a potent HIV-1 inhibitor with an EC50 value of 0.0047 µM for HIV-1 IIIB. HIV-1 inhibitor-74 shows cytotoxicity. HIV-1 inhibitor-74 inhibits WT HIV-1 RT activity with an IC50 value of 0.134 µM. HIV-1 inhibitor-74 shows broad-spectrum anti HIV-1 activity.
    HIV-1 inhibitor-74
  • HY-162030
    MMT3-72 2996158-39-3 98%
    MMT3-72 is a weak inhibitor of JAK1. MMT3-72 has superior efficacy and reduced p-STAT3 in DSS-induced colitis.
    MMT3-72
  • HY-162069
    Antiviral agent 47 89419-23-8 98%
    Antiviral agent 47 (Compound 26) is an antiviral agent, which inhibits HSV-1 with ID50 of 16 μM, through suppression of herpes virus replication.
    Antiviral agent 47
Cat. No. Product Name / Synonyms Application Reactivity